Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EBITDA (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed EBITDA for 7 consecutive years, with -$20.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 21.31% to -$20.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$77.4 million through Dec 2025, down 521.72% year-over-year, with the annual reading at -$74.8 million for FY2025, 691.16% down from the prior year.
  • EBITDA for Q4 2025 was -$20.4 million at Fulcrum Therapeutics, down from -$19.4 million in the prior quarter.
  • The five-year high for EBITDA was $52.5 million in Q2 2024, with the low at -$34.0 million in Q2 2022.
  • Average EBITDA over 5 years is -$19.7 million, with a median of -$22.4 million recorded in 2021.
  • The sharpest move saw EBITDA surged 292.33% in 2024, then plummeted 137.75% in 2025.
  • Over 5 years, EBITDA stood at -$23.8 million in 2021, then decreased by 17.56% to -$28.0 million in 2022, then dropped by 0.07% to -$28.0 million in 2023, then soared by 39.92% to -$16.8 million in 2024, then decreased by 21.31% to -$20.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$20.4 million, -$19.4 million, and -$19.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.